Abbott loses pharma head
This article was originally published in The Gray Sheet
Executive Summary
Jeffrey Leiden, PhD, steps down as president of the firm's pharmaceutical products group, to be replaced by medical products group head Richard Gonzalez, effective March 27. The move makes Gonzalez president and COO for all operations of the corporation, Abbott says. The change comes as the company begins to focus more on the medical device side of its business with its impending $7 bil. acquisition of Guidant's vascular and endovascular businesses - the spoils of Boston Scientific's acquisition of Guidant (1"The Gray Sheet" March 20, 2006, p. 18)...
You may also be interested in...
Weird Xience: Abbott Will Launch The Guidant Stent Before Boston Scientific
Boston Scientific plans to launch the Xience drug-eluting stent three months after the same stent is introduced by licensing partner Abbott, giving Abbott a short-term sales advantage
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.